Published 27 March 2017
Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program.
Ignyta had previously disclosed it was in discussions with Lilly regarding the optimal path forward for taladegib in the context of its pipeline priorities, which are focused substantially on molecularly targeted therapies, including its lead product candidate, entrectinib.
The agreement amends and restates the prior license, development and commercialization agreement, dated November 6, 2015, by and between Ignyta and Lilly.
Taladegib is a potent, orally bioavailable small molecule hedgehog/smoothened antagonist that has achieved clinical proof-of-concept and a recommended Phase 2 dose based on results from prior clinical studies.
Jonathan Lim, M.D., Chairman and CEO of Ignyta said: “Ignyta is excited to continue to develop potential combinations of taladegib with other products to address residual disease, while exploring strategic options for single agent taladegib oral and the topical formulation of taladegib by sub-licensing or selling the franchise to dermatology-focused companies who may have an interest in superficial, nodular, and advanced basal cell carcinoma (BCC).
“We have received inbound interest on these assets in these BCC indications, and will be weighing the merits of these potential partnerships with other opportunities to develop taladegib internally for the benefit of patients with rare cancers outside of BCC.
“We are pleased to have achieved an amicable resolution with Lilly to provide Ignyta with a clear path forward for pursuing these various strategic options for taladegib.”
Source: Company Press Release